GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » Construction In Progress

Genetic Signatures (ASX:GSS) Construction In Progress : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures Construction In Progress?


Genetic Signatures Construction In Progress Historical Data

The historical data trend for Genetic Signatures's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures Construction In Progress Chart

Genetic Signatures Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only - - - - -

Genetic Signatures Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Genetic Signatures Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Genetic Signatures (ASX:GSS) Business Description

Traded in Other Exchanges
N/A
Address
7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.